A mouse anti-albicans, tropical Candida albicans mannan hybridoma cell line and monoclonal antibody

By developing mouse anti-white, tropical Candida mannan hybridoma cell line JE10 and its monoclonal antibodies, the problem of long diagnosis time and low positive rate in the prior art is solved, and a highly efficient and specific detection is provided Methods, the patient's mortality rate was reduced.

CN118516315BActive Publication Date: 2024-11-29GENOBIO PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410993384.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-29
Estimated Expiration
2044-07-24

AI Technical Summary

Technical Problem

The existing diagnostic methods of candida rely on fungal culture, with a long time and low positive rate, resulting in delayed early detection and treatment and increased patient mortality.

Method used

A mouse anti-white, Candida tropical mannan hybridoma cell line JE10 and its monoclonal antibody were developed to detect Candida albicans and Candida tropical mannans, and its inclusiveness and specificity were identified by ELISA method. Kits are provided for detection.

Benefits of technology

The monoclonal antibody reacts strongly with Candida albican mannan and Candida tropical mannan and does not cross-react with other polysaccharides, providing an efficient, specific early detection method that reduces mortality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118516315B_ABST
    Figure CN118516315B_ABST
Patent Text Reader

Abstract

The present invention provides a hybridoma cell line and monoclonal antibody against candida albicans and tropical candida mannans. The hybridoma cell line and its variable region sequence which stably secrete monoclonal antibodies against candida albicans and tropical candida mannans are obtained by screening mouse hybridoma monoclonal antibodies and cloning Ig variable region genes by RT-PCR method. The antibody tolerance, specificity and antibody titer are identified by ELISA method, which lays a foundation for the research and development of genetic engineering antibodies against candida albicans and tropical candida mannans.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of antibody preparation, and particularly relates to mouse anti-albicans and tropical candida mannan hybridoma cell lines and monoclonal antibodies. Background Art

[0002] Candida spp. Candida ) belongs to the phylum Ascomycota, also known as Candida, and is a common conditional pathogen. It causes disease by invading the host's mucous membranes and tissues, triggering local and systemic inflammatory responses. The pathogenicity of different strains of this genus varies greatly, among which Candida albicans is the most common, followed by Candida tropicalis.

[0003] Mannan often exists in the form of glycoprotein in a variety of microorganisms and is another important antigenic determinant on the surface of Candida besides glucan. Mannan is an important antigen in the body's inherent immunity and adaptive immunity and can induce a strong antibody response.

[0004] In recent years, the incidence of Candida albicans has been gradually increasing, and the mortality rate has remained high. The mortality rate is closely related to the duration of antifungal treatment. The current gold standard for diagnosing candida is still fungal culture, which has a long culture time and a low positive rate. Inappropriate or delayed treatment will increase the mortality rate of patients. Therefore, early rapid detection and accurate treatment measures are the key to reducing mortality. This study invented the application of monoclonal antibodies in early rapid detection kits, providing a new solution for detecting Candida infection. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a mouse anti-albicans and tropical Candida mannan hybridoma cell line and monoclonal antibody.

[0006] The technical solution adopted by the present invention is: a mouse anti-albicans and tropical Candida mannan hybridoma cell line, named JE10, classified as a hybridoma cell, the preservation date is November 8, 2023, the preservation unit is the General Microbiology Center of the China Microbiological Culture Collection Administration (CGMCC), and the preservation number is CGMCC No.45744.

[0007] A mouse anti-albicans and tropical Candida mannan monoclonal antibody, antibody JE10 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises CDRH1 as shown in SEQ ID NO:1, CDRH2 as shown in SEQ ID NO:2 and CDRH3 as shown in SEQ ID NO:3, and the light chain variable region comprises CDRL1 as shown in SEQ ID NO:4, CDRL2 as shown in SEQ ID NO:5 and CDRL3 as shown in SEQ ID NO:6;

[0008] SEQ ID NO:1 DFSFTNYWMN

[0009] SEQ ID NO:2 EIRLKSNNYATYYAESVKG

[0010] SEQ ID NO:3 NLGMDY

[0011] SEQ ID NO:4 SASSSVTYMF

[0012] SEQ ID NO:5 DTSNLAS

[0013] SEQ ID NO:6 QQWKWDTYPRT

[0014] Preferably, the amino acid sequence of the heavy chain variable region of antibody JE10 is shown in SEQ ID NO: 7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 9;

[0015] Heavy chain variable region sequence

[0016] SEQ ID NO:7

[0017] MKLSCVASDFSFTNYWMNWVRQSPEKGLEWVAEIRLKSNNYATYYAESVKGRFTISRDDFKCSIYLQMNNLRVEDTGVYFCTSNLGMDYWGQGTSVTVSSAKTTAP

[0018] Light chain variable region sequence

[0019] SEQ ID NO:9

[0020] QIVLTQSPAIMSASPGEKVTLTCSASSSVTYMFWYQQKPGSSPRLLIHDTSNLASGVPVRFSGSGSGTSYSLTLSRVEAEDAATYYCQQWKWDTYPRTFGGGTKLEIKRADAAPTVS

[0021] Preferably, the antibody JE10 is produced by the mouse anti-Candida albicans and tropicalis mannan hybridoma cell line with a deposit number of CGMCC No.45744.

[0022] A nucleic acid molecule comprising nucleotides encoding mouse anti-albicans and tropical Candida mannan monoclonal antibodies.

[0023] Preferably, the nucleotide sequence of the heavy chain variable region of the antibody JE10 encoded by the nucleic acid molecule is as shown in SEQ ID NO: 8, and the nucleotide sequence of the light chain variable region of the antibody JE10 encoded by the nucleic acid molecule is as shown in SEQ ID NO: 10;

[0024] Heavy chain variable region nucleotide sequence

[0025] SEQ ID NO:8

[0026] ATGAAACTCTCCTGTGTTGCCCTGATTTCTCTTTCACTAATTATTGGATGAACTGGGTCCCGCCAGTCTCCAGAGAAGGGACTTGAGTGGGTTGCTGAAATTAGATTGAAATCTAATAATTATGCAACATATTATGCGGAGTCTGTGAAAGGGAGGTTC ACCATCTCAAGAGATGATTTCAAATGTAGTATCTACTTACAAATGAACAACTTAAGGGTTGAAGACACTGGCGTTTATTTCTGTACTTCTAACCTAGGTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCTTCAGCCAAAACGACAGCCCCA

[0027] Light chain variable region nucleotide sequence

[0028] SEQ ID NO:10

[0029] CAAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCCTGACCTGCAGTGCCAGCTCAAGTGTGACTTACATGTTCTGGTACCAGCAGAAGCCAGGATCCTCCCCAGACTCCTGATTCATGACACATCCAACCTGGCTTCTGGAGTCCCTG TTCGCTTCAGTGGCAGTGGCTCTGGGACCTCTTACTCTCTCACACTCAGCCGAGTGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAATGGAAGTGGGATACTTACCCACGGACGTTCGGTGGAGGCACCAAACTGGAAATCAAACGGGCTGATGCTGCACCAACTGTATCC

[0030] A kit for detecting Candida albicans mannan and / or Candida tropicalis mannan comprises mouse anti-Candida albicans and Candida tropicalis mannan monoclonal antibodies.

[0031] The advantages and positive effects of the present invention are as follows: providing mouse anti-albic and tropical Candida mannan monoclonal antibodies, which react strongly with Candida albicans mannan and tropical Candida mannan, do not react with Candida glabrata mannan, Candida krusei mannan and Candida parapsilosis mannan, and have no cross reaction with cryptococcal capsular polysaccharide, 1,3-β-D glucan, Aspergillus galactomannan, lipopolysaccharide and peptidoglycan. Based on these characteristics, the present invention lays a foundation for the preparation of genetic engineering antibodies against albic and tropical Candida mannan. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 Protein electrophoresis of antibody JE10 after purification; 1. Marker; 2. JE10;

[0033] Figure 2 Inclusivity assay results for antibody JE10;

[0034] Figure 3 Results of cross-reactivity assay of antibody JE10;

[0035] Figure 4 The antibody titer determination results of antibody JE10;

[0036] Biological material: JE10, classified as hybridoma cell, deposited on November 8, 2023, deposited by China General Microbiology Center (CGMCC), deposit number is CGMCC No. 45744. DETAILED DESCRIPTION

[0037] The following is a description of embodiments of the present invention.

[0038] The present invention relates to a mouse anti-albicans and tropical Candida mannan hybridoma cell line, wherein one biological material is named JE10, which belongs to a hybridoma cell, and its preservation number is CGMCC No. 45744; its preservation place is the General Microbiology Center of China National Committee for the Preservation of Microorganisms, the address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing; its preservation date is November 8, 2023, and it is detected to be alive.

[0039] The mouse anti-albicans and tropical Candida mannan hybridoma cell strain involved in the present invention obtains a hybridoma cell strain and its variable region sequence that stably secretes mouse anti-albicans and tropical Candida mannan monoclonal antibodies through mouse hybridoma monoclonal antibody screening and RT-PCR cloning of Ig variable region genes, and identifies the antibody tolerance and specificity by ELISA method, thus laying a foundation for the research and development of anti-albicans and tropical Candida mannan genetic engineering antibodies.

[0040] The antibody JE10 produced by the mouse anti-albicans and tropical Candida mannan hybridoma cell strain is produced by the mouse anti-albicans and tropical Candida mannan hybridoma cell strain with a deposit number of CGMCC No.45744; the antibody JE10 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises CDRH1 as shown in SEQ ID NO:1, CDRH2 as shown in SEQ ID NO:2 and CDRH3 as shown in SEQ ID NO:3, and the light chain variable region comprises CDRL1 as shown in SEQ ID NO:4, CDRL2 as shown in SEQ ID NO:5 and CDRL3 as shown in SEQ ID NO:6;

[0041] SEQ ID NO:1 DFSFTNYWMN

[0042] SEQ ID NO:2 EIRLKSNNYATYYAESVKG

[0043] SEQ ID NO:3 NLGMDY

[0044] SEQ ID NO:4 SASSSVTYMF

[0045] SEQ ID NO:5 DTSNLAS

[0046] SEQ ID NO:6 QQWKWDTYPRT

[0047] The amino acid sequence of the heavy chain variable region of antibody JE10 is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:9;

[0048] Heavy chain variable region sequence SEQ ID NO: 7

[0049] MKLSCVASDFSFTNYWMNWVRQSPEKGLEWVAEIRLKSNNYATYYAESVKGRFTISRDDFKCSIYLQMNNLRVEDTGVYFCTSNLGMDYWGQGTSVTVSSAKTTAP

[0050] Light chain variable region sequence SEQ ID NO: 9

[0051] QIVLTQSPAIMSASPGEKVTLTCSASSSVTYMFWYQQKPGSSPRLLIHDTSNLASGVPVRFSGSGSGTSYSLTLSRVEAEDAATYYCQQWKWDTYPRTFGGGTKLEIKRADAAPTVS

[0052] The nucleotide sequence encoding the heavy chain variable region of antibody JE10 is shown in SEQ ID NO:8, and the nucleotide sequence encoding the light chain variable region of antibody JE10 is shown in SEQ ID NO:10;

[0053] Heavy chain variable region nucleotide sequence SEQ ID NO: 8

[0054] ATGAAACTCTCCTGTGTTGCCCTGATTTCTCTTTCACTAATTATTGGATGAACTGGGTCCCGCCAGTCTCCAGAGAAGGGACTTGAGTGGGTTGCTGAAATTAGATTGAAATCTAATAATTATGCAACATATTATGCGGAGTCTGTGAAAGGGAGGTTC ACCATCTCAAGAGATGATTTCAAATGTAGTATCTACTTACAAATGAACAACTTAAGGGTTGAAGACACTGGCGTTTATTTCTGTACTTCTAACCTAGGTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCTTCAGCCAAAACGACAGCCCCA

[0055] Light chain variable region nucleotide sequence SEQ ID NO: 10

[0056] CAAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCCTGACCTGCAGTGCCAGCTCAAGTGTGACTTACATGTTCTGGTACCAGCAGAAGCCAGGATCCTCCCCAGACTCCTGATTCATGACACATCCAACCTGGCTTCTGGAGTCCCTG TTCGCTTCAGTGGCAGTGGCTCTGGGACCTCTTACTCTCTCACACTCAGCCGAGTGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAATGGAAGTGGGATACTTACCCACGGACGTTCGGTGGAGGCACCAAACTGGAAATCAAACGGGCTGATGCTGCACCAACTGTATCC

[0057] The mouse anti-albicans and tropical Candida mannan monoclonal antibody produced by hybridoma cell JE10 reacts strongly with albicans and tropical Candida mannan, does not react with glabrata mannan, krusei mannan, and Candida parapsilosis mannan, and has no cross reaction with cryptococcal capsular polysaccharide, 1,3-β-D glucan, Aspergillus galactomannan, lipopolysaccharide, and peptidoglycan. Based on these characteristics, this monoclonal antibody can be used for the detection of albicans and tropical Candida mannan.

[0058] The scheme of the present invention is further described below in conjunction with the accompanying drawings, wherein the experimental methods without specific operating steps are all carried out in accordance with the corresponding product instructions, and the instruments, reagents, and consumables used in the examples can all be purchased from commercial companies unless otherwise specified.

[0059] Example 1: Screening of mouse anti-albicans and tropical Candida mannan hybridoma cell lines

[0060] Take 3ml of 10mg / ml Candida albicans mannan, put it in an ice bath, and slowly add 150ul of 100mg / ml CDAP. After 1min, add 0.1M TEA to adjust pH to 9.0, mix well, add 2.5ml 1M ADH, adjust pH to 8.0, react at 4℃ for 2h, and dialyze in 0.01M PBS3500D for 24h. Add 233ul 21.5mg / ml BSA to the above solution, add 122mg EDAC to make the final concentration 0.15M, and react at 4℃ for 2h. Dialyze overnight in 0.02M PBS 50kD, and identify after centrifugation. Used for animal immunization.

[0061] The first immunization dose is 50ug / mouse, the adjuvant is Freund's complete adjuvant, subcutaneous multiple injection, and the interval between the second immunization is 2 weeks; the second immunization dose is 50ug / mouse, the adjuvant is Freund's incomplete adjuvant, intraperitoneal injection, and the interval between the third immunization is 2 weeks; the third and subsequent immunization doses, routes, and adjuvants are the same as the second immunization method, and the interval between the two immunizations is 2 weeks until the fourth immunization. Blood was collected from the tail vein of the mouse to determine the titer, and cell fusion was performed when the titer reached 1:8000 or above.

[0062] Immunize 50ug polysaccharide 3 days before fusion, without adjuvant. After blood was collected from the mouse eyeball, spleen cells of the successfully immunized mice were taken for cell fusion with myeloma SP2 / 0 cells (at a ratio of 10:1). During the fusion, 50% PEG was added to the spleen cells and myeloma cell clusters that were mixed and the supernatant was discarded in a 37°C water bath within 1 minute, and the mixture was shaken in a 37°C water bath for 1 minute, and then 10ml of serum-free 1640 medium was added within 2 minutes. Centrifuge at 800rpm for 6 minutes, discard the supernatant, resuspend the cells with 1640 medium containing HAT, and pipette into a 96-well plate (2.5x10 7 Cells were cultured at 37°C and 5% CO2. The medium was half-changed on the third day after fusion and fully changed on the seventh day.

[0063] When the clones in the fusion plate are large enough, take 100μl of supernatant from each well for detection, and the method is the same as the titer detection method. The OD value of the negative well is more than twice that of the positive well, and the next cloning culture is carried out. The hybridoma clones that are screened positive are expanded from the 96-well plate to the 24-well plate for 3-5 days, and the culture supernatant is screened and tested again. The clones that are tested positive are then cultured for the next subclone, and the remaining cells are frozen. Collect the hybridoma cells in the 24-well plate, count the cells, and adjust the cell density to 10 / mL; spread the cells into the 96-well plate, 100μl per well, and culture in an incubator at 37°C and 5% CO2; after about 10 days of culture, clone formation can be seen, select the wells with only a single clone, aspirate the culture supernatant, and the detection method is the same as before. Select the positive clones and expand them to 24-well plates for culture. After the supernatant is tested again, select the positive clones for the second round of subclone culture. Generally, after multiple rounds of subclone culture, until all the test wells are positive, a stable hybridoma cell line is obtained. The positive hybridoma culture supernatant was selected, and the antibody subtype detection paper was used to detect the antibody subtype. The monoclonal antibody in the present invention was numbered JE10, the heavy chain was mouse IgG1 subtype, and the light chain was κ chain.

[0064] Example 2: Preparation of mouse anti-albicans and tropical Candida mannan monoclonal antibodies

[0065] 2.1 Ascites preparation and purification

[0066] Wash the hybridoma cells with sterile PBS solution and add 5x10 6 / 0.5ml / mouse was intraperitoneally injected into Balb / c mice pre-sensitized with liquid paraffin. After 7 to 10 days, the ascites was collected and the supernatant was collected at 3000rpm for 10min at room temperature. The antibodies in the ascites were crudely purified using the caprylic acid-ammonium sulfate method. The crudely purified antibodies were further purified using the AKTA protein purification system and 1ml Protein G purification pre-packed column according to the purification manual provided by GE. The results after purification are shown in Figure 1 .

[0067] 2.2 Determination of the inclusivity of the reaction with different Candida mannans

[0068] The indirect ELISA method was used to determine the tolerance of 5 types of Candida mannan. 1ug / mL of Candida albicans mannan, Candida glabrata mannan, Candida krusei mannan, Candida tropicalis mannan, and Candida parapsilosis mannan were coated, 100uL / well. 5% skim milk powder was used as the blocking solution. The antibody was first diluted to 1mg / mL and then diluted 1:1000 as the primary antibody. The Abcam enzyme-labeled antibody was used as the secondary antibody at a dilution of 1:20000. After the reaction was completed, the absorbance was read at OD450nm. The uncoated group was set as the control. The OD value of the Candida mannan was more than 2.1 times that of the control group, indicating that the antibody reacted to this type of Candida mannan. The results are attached. Figure 2 Antibody JE10 reacts strongly with Candida albicans mannan and Candida tropicalis mannan, but does not react with Candida glabrata mannan, Candida krusei mannan, and Candida parapsilosis mannan.

[0069] 2.3 Determination of cross-reactivity with other polysaccharides

[0070] The cross-reactivity with other polysaccharides was determined by indirect ELISA. Cryptococcal capsular polysaccharide, 1,3-β-D glucan, Aspergillus galactomannan, lipopolysaccharide, and peptidoglycan were coated at 1ug / mL, 100uL / well. 5% skim milk powder was used as blocking solution. The antibody to be tested was first diluted to 1mg / mL and then diluted 1:1000 times as the primary antibody. Abcam enzyme-labeled antibody was used as the secondary antibody at a dilution of 1:20000. After the reaction, the absorbance was read at OD450nm. Results are shown in Figure 3 It can be seen that antibody JE10 has no cross-reaction with other polysaccharides, indicating that the antibody has strong specificity.

[0071] 2.4 Monoclonal Antibody Titer Detection

[0072] The titer of ascites was determined by indirect ELISA. 1ug / ml of white and tropical Candida mannan was coated, 100ul / well. 1% BSA was used as blocking solution. The ascites was diluted from 1:1000, with a total of 12 dilution gradients. Promega enzyme-labeled antibody was used as the secondary antibody after dilution of 1:6000. The OD was read at 450nm. At the same time, the uncoated group was set as a control. The OD value when the antibody was diluted 2048000 times was more than 2.1 times that of the control group, indicating that the titer of ascites has reached 1:2048000. The results are attached. Figure 4 The titer of the antibody JE10 prepared from ascites and Candida albicans and Candida tropicalis mannan was as high as 10 6 .

[0073] Example 3: Genetic verification of mouse anti-albicans and tropical Candida mannan monoclonal antibodies

[0074] Cloning of Ig variable region genes by RT-PCR

[0075] Total RNA extraction and single-stranded cDNA synthesis:

[0076] The total RNA of JE10 hybridoma cell line was extracted by Trizol method (kit purchased from Invitrogen), and the total RNA was reversed into cDNA library by M-MLV reverse transcriptase (purchased from Invitrogen).

[0077] Heavy chain backbone region upstream primer

[0078] P1: 5' SAGGGTGMAGCTKCASSARTCWGG 3' (SEQ ID NO: 11)

[0079] Heavy chain variable region downstream primer

[0080] P2: 5'TGGGGSTGTYGTTTTGGCTGMRGAGACRGTGA3' (SEQ ID NO: 12)

[0081] Light chain leader peptide upstream primer

[0082] P3: 5' ATGGATTTTCAAGTGCAGATTTTCAG 3' (SEQ ID NO: 13)

[0083] Light chain variable region downstream primer

[0084] P4: 5'GGATACAGTTGGTGCAGCATCAGCCCGTTT3' (SEQ ID NO:14)

[0085] Prepare PCR reaction system (50 μl) as follows:

[0086] cDNA: 2μl; upstream primer (10μM): 2μl; downstream primer (10μM): 2μl; dNTP mixture: 2μl; pfuDNA polymerase (5U / μl): 1μl; 10X pfu Buffer Ⅱ: 5μl; ddH2O: make up to 50μl.

[0087] Reaction conditions: pre-denaturation at 95°C for 5 min; repeat the following cycle 35 times: 95°C for 30 s, 58°C for 30 s, 72°C for 1 min; finally, extension at 72°C for 10 min.

[0088] Agarose gel electrophoresis was used to separate and recover the VL and VH fragments. The recovered VL and VH fragments were connected to the pMD19-T (simple) vector (Takara Company) respectively. The connection system is as follows:

[0089] 70 ng of VL PCR product / VH PCR product, 1 μl of pMD19-T (simple) vector, 5 μl of Solution I ligation reaction solution; add ddH2O to 10 μl, and ligate at 4°C overnight.

[0090] The ligation product was transformed into E. coli DH5α competent bacteria, cultured overnight at 37°C, and a single colony was picked. After shaking at 37°C for 2 hours, PCR identification of the bacterial solution was performed, and the cDNA of the corresponding antibody was used as a positive control. The reaction system (25 μl) was prepared as follows:

[0091] Bacterial solution: 1 μl, upstream primer (10 μM): 1 μl; downstream primer (10 μM): 1 μl; dNTP Mixture (2.5 μm each) 2 μl; Taq DNA polymerase (5 U / μl): 0.5 μl; 10× Taq Buffer (Mg 2+ plus): 2.5 μl; add water to 25 μl. The reaction conditions are the same as before.

[0092] The clones with positive PCR were selected for expansion culture, and the plasmids of positive clones were extracted with a plasmid extraction kit (Takara) and sent for sequencing. At least 5 clone samples of each chain of each antibody were sent for testing, and the sequencing results of at least three samples were the same. The heavy chain and light chain variable region sequences of antibody JE10 were successfully cloned and matched the characteristics of typical antibody variable region sequences after comparison.

[0093] The embodiments of the present invention are described in detail above, but the contents are only preferred embodiments of the present invention and cannot be considered to limit the scope of implementation of the present invention. All equivalent changes and improvements made according to the scope of application of the present invention should still fall within the scope of the patent coverage of the present invention.

Claims

1. A mouse anti-candida albicans and tropical candida mannan hybridoma cell line, characterized in that: Named as JE10, the deposit number is CGMCC No.45744.

2. A mouse anti-albicans, tropical Candida mannan monoclonal antibody, characterized in that: Antibody JE10 includes a heavy chain variable region and a light chain variable region, the heavy chain variable region includes CDRH1 as shown in SEQ ID NO: 1, CDRH2 as shown in SEQ ID NO: 2, and CDRH3 as shown in SEQ ID NO: 3, and the light chain variable region includes CDRL1 as shown in SEQ ID NO: 4, CDRL2 as shown in SEQ ID NO: 5, and CDRL3 as shown in SEQ ID NO:

6.

3. A mouse anti-albicans and tropical Candida mannan monoclonal antibody according to claim 2, characterized in that: The amino acid sequence of the heavy chain variable region of antibody JE10 is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

9.

4. A mouse anti-albicans, tropical Candida mannan monoclonal antibody according to claim 2 or 3, characterized in that: Antibody JE10 is produced by the mouse anti-albicans and tropical Candida mannan hybridoma cell line with the deposit number of CGMCC No.45744.

5. A nucleic acid molecule, characterized in that: The invention comprises a polynucleotide encoding the mouse anti-albicans and tropical Candida mannan monoclonal antibody according to claim 2 or 3.

6. The nucleic acid molecule according to claim 5, characterized in that: The nucleotide sequence of the heavy chain variable region of the antibody JE10 encoded by the nucleic acid molecule is shown in SEQ ID NO:8, and the nucleotide sequence of the light chain variable region of the antibody JE10 encoded by the nucleic acid molecule is shown in SEQ ID NO:

10.

7. A kit for detecting Candida albicans mannan and / or Candida tropicalis mannan, characterized in that: The invention comprises the mouse anti-albicans and tropical Candida mannan monoclonal antibodies as described in any one of claims 2-4.

Citation Information

Patent Citations

  • Monoclonal antibody of candida mannan and preparation method of monoclonal antibody

    CN105968198A

  • Preparation method and application of specific monoclonal antibody against candida albicans enolase

    CN110204616A